1. Key Insights
2. Executive Summary of CRPC
3. CRPC: Disease Background and Overview
3.1. Introduction
3.1.1. Signs and Symptoms of Prostate Cancer
3.1.2. Risk Factors and Causes of Prostate Cancer
3.1.3. Pathophysiology of Prostate Cancer
3.1.4. Prostate Neoplasia
3.1.5. Genetics of Prostate Cancer
4. Diagnosis of Prostate Cancer
4.1. Screening Tests for Prostate Cancer
4.2. Tests to Diagnose Prostate Cancer
4.3. Stages and Grades of Prostate Cancer
5. Epidemiology and Patient Population
5.1. Key Findings
5.2. Assumptions and Rationale: 7MM
5.3. Epidemiology Scenario: 7MM
5.3.1. Total Prevalent Cases of Prostate Cancer in the 7MM
5.3.2. Total Diagnosed Cases of Prostate Cancer by Clinical Stages in the 7MM
5.3.3. Total Non-metastatic and Metastatic Cases of CRPC in the 7MM
5.3.4. Total Treated cases of Non-metastatic CRPC Patients in the 7MM
5.3.5. Total Treated Cases of Metastatic CRPC Patients in the 7MM
5.4. The United States Epidemiology
5.4.1. Total Diagnosed Cases of Prostate Cancer in the United States
5.4.2. Age-specific Cases of Prostate Cancer in the United States
5.4.3. Total Diagnosed Cases of Prostate Cancer by Clinical Stages in the United States
5.4.4. Total Non-metastatic and Metastatic Cases of CRPC in the United States
5.4.5. Total Treated cases of Non-metastatic CRPC Patients in the United States
5.4.6. Total Treated Cases of Metastatic CRPC Patients in the United States
6. EU-5 Country-wise Epidemiology
6.1. Germany
6.1.1. Total Diagnosed Prevalent cases of Prostate Cancer in Germany
6.1.2. Age-specific Diagnosed Prevalent cases of Prostate Cancer in Germany
6.1.3. Total Diagnosed Prevalent cases of Prostate Cancer by Clinical Stages in Germany
6.1.4. Total Non-metastatic and Metastatic Cases of CRPC in Germany
6.1.5. Total Treated cases of Non-metastatic CRPC Patients in Germany
6.1.6. Total Treated Cases of Metastatic CRPC Patients in Germany
6.2. France
6.2.1. Total Diagnosed Prevalent cases of Prostate Cancer in France
6.2.2. Age-specific Diagnosed Prevalent cases of Prostate Cancer in France
6.2.3. Total Diagnosed Prevalent cases of Prostate Cancer by Clinical Stages in France
6.2.4. Total Non-metastatic and Metastatic Cases of CRPC in France
6.2.5. Total Treated cases of Non-metastatic CRPC Patients in France
6.2.6. Total Treated Cases of Metastatic CRPC Patients in France
6.3. Italy
6.3.1. Total Diagnosed Prevalent cases of Prostate Cancer in Italy
6.3.2. Age-specific Diagnosed Prevalent cases of Prostate Cancer in Italy
6.3.3. Total Diagnosed Prevalent cases of Prostate Cancer by Clinical Stages in Italy
6.3.4. Total Non-metastatic and Metastatic Cases of CRPC in Italy
6.3.5. Total Treated cases of Non-metastatic CRPC Patients in Italy
6.3.6. Total Treated Cases of Metastatic CRPC Patients in Italy
6.4. Spain
6.4.1. Total Diagnosed Prevalent cases of Prostate Cancer in Spain
6.4.2. Age-specific Diagnosed Prevalent cases of Prostate Cancer in Spain
6.4.3. Total Diagnosed Prevalent cases of Prostate Cancer by Clinical Stages in Spain
6.4.4. Total Non-metastatic and Metastatic Cases of CRPC in Spain
6.4.5. Total Treated cases of Non-metastatic CRPC Patients in Spain
6.4.6. Total Treated Cases of Metastatic CRPC Patients in Spain
6.5. United Kingdom
6.5.1. Total Diagnosed Prevalent cases of Prostate Cancer in the United Kingdom
6.5.2. Age-specific Diagnosed Prevalent cases of Prostate Cancer in the United Kingdom
6.5.3. Total Diagnosed Prevalent cases of Prostate Cancer by Clinical Stages in the United Kingdom
6.5.4. Total Non-metastatic and Metastatic Cases of CRPC in the United Kingdom
6.5.5. Total Treated cases of Non-metastatic CRPC Patients in the United Kingdom
6.5.6. Total Treated Cases of Metastatic CRPC Patients in the United Kingdom
6.6. Japan
6.6.1. Total Diagnosed Prevalent cases of Prostate Cancer in Japan
6.6.2. Age-specific Diagnosed Prevalent cases of Prostate Cancer in Japan
6.6.3. Total Diagnosed Prevalent cases of Prostate Cancer by Clinical Stages in Japan
6.6.4. Total Non-metastatic and Metastatic Cases of CRPC in Japan
6.6.5. Total Treated cases of Non-metastatic CRPC Patients in Japan
6.6.6. Total Treated Cases of Metastatic CRPC Patients in Japan
7. Appendix
7.1. Bibliography
7.2. Report Methodology
8. DelveInsight Capabilities
9. Disclaimer
10. About DelveInsight
1. Key Insights2. Executive Summary of CRPC
3. CRPC: Disease Background and Overview
3.1. Introduction
3.1.1. Signs and Symptoms of Prostate Cancer
3.1.2. Risk Factors and Causes of Prostate Cancer
3.1.3. Pathophysiology of Prostate Cancer
3.1.4. Prostate Neoplasia
3.1.5. Genetics of Prostate Cancer
4. Diagnosis of Prostate Cancer
4.1. Screening Tests for Prostate Cancer
4.2. Tests to Diagnose Prostate Cancer
4.3. Stages and Grades of Prostate Cancer
5. Epidemiology and Patient Population
5.1. Key Findings
5.2. Assumptions and Rationale: 7MM
5.3. Epidemiology Scenario: 7MM
5.3.1. Total Prevalent Cases of Prostate Cancer in the 7MM
5.3.2. Total Diagnosed Cases of Prostate Cancer by Clinical Stages in the 7MM
5.3.3. Total Non-metastatic and Metastatic Cases of CRPC in the 7MM
5.3.4. Total Treated cases of Non-metastatic CRPC Patients in the 7MM
5.3.5. Total Treated Cases of Metastatic CRPC Patients in the 7MM
5.4. The United States Epidemiology
5.4.1. Total Diagnosed Cases of Prostate Cancer in the United States
5.4.2. Age-specific Cases of Prostate Cancer in the United States
5.4.3. Total Diagnosed Cases of Prostate Cancer by Clinical Stages in the United States
5.4.4. Total Non-metastatic and Metastatic Cases of CRPC in the United States
5.4.5. Total Treated cases of Non-metastatic CRPC Patients in the United States
5.4.6. Total Treated Cases of Metastatic CRPC Patients in the United States
6. EU-5 Country-wise Epidemiology
6.1. Germany
6.1.1. Total Diagnosed Prevalent cases of Prostate Cancer in Germany
6.1.2. Age-specific Diagnosed Prevalent cases of Prostate Cancer in Germany
6.1.3. Total Diagnosed Prevalent cases of Prostate Cancer by Clinical Stages in Germany
6.1.4. Total Non-metastatic and Metastatic Cases of CRPC in Germany
6.1.5. Total Treated cases of Non-metastatic CRPC Patients in Germany
6.1.6. Total Treated Cases of Metastatic CRPC Patients in Germany
6.2. France
6.2.1. Total Diagnosed Prevalent cases of Prostate Cancer in France
6.2.2. Age-specific Diagnosed Prevalent cases of Prostate Cancer in France
6.2.3. Total Diagnosed Prevalent cases of Prostate Cancer by Clinical Stages in France
6.2.4. Total Non-metastatic and Metastatic Cases of CRPC in France
6.2.5. Total Treated cases of Non-metastatic CRPC Patients in France
6.2.6. Total Treated Cases of Metastatic CRPC Patients in France
6.3. Italy
6.3.1. Total Diagnosed Prevalent cases of Prostate Cancer in Italy
6.3.2. Age-specific Diagnosed Prevalent cases of Prostate Cancer in Italy
6.3.3. Total Diagnosed Prevalent cases of Prostate Cancer by Clinical Stages in Italy
6.3.4. Total Non-metastatic and Metastatic Cases of CRPC in Italy
6.3.5. Total Treated cases of Non-metastatic CRPC Patients in Italy
6.3.6. Total Treated Cases of Metastatic CRPC Patients in Italy
6.4. Spain
6.4.1. Total Diagnosed Prevalent cases of Prostate Cancer in Spain
6.4.2. Age-specific Diagnosed Prevalent cases of Prostate Cancer in Spain
6.4.3. Total Diagnosed Prevalent cases of Prostate Cancer by Clinical Stages in Spain
6.4.4. Total Non-metastatic and Metastatic Cases of CRPC in Spain
6.4.5. Total Treated cases of Non-metastatic CRPC Patients in Spain
6.4.6. Total Treated Cases of Metastatic CRPC Patients in Spain
6.5. United Kingdom
6.5.1. Total Diagnosed Prevalent cases of Prostate Cancer in the United Kingdom
6.5.2. Age-specific Diagnosed Prevalent cases of Prostate Cancer in the United Kingdom
6.5.3. Total Diagnosed Prevalent cases of Prostate Cancer by Clinical Stages in the United Kingdom
6.5.4. Total Non-metastatic and Metastatic Cases of CRPC in the United Kingdom
6.5.5. Total Treated cases of Non-metastatic CRPC Patients in the United Kingdom
6.5.6. Total Treated Cases of Metastatic CRPC Patients in the United Kingdom
6.6. Japan
6.6.1. Total Diagnosed Prevalent cases of Prostate Cancer in Japan
6.6.2. Age-specific Diagnosed Prevalent cases of Prostate Cancer in Japan
6.6.3. Total Diagnosed Prevalent cases of Prostate Cancer by Clinical Stages in Japan
6.6.4. Total Non-metastatic and Metastatic Cases of CRPC in Japan
6.6.5. Total Treated cases of Non-metastatic CRPC Patients in Japan
6.6.6. Total Treated Cases of Metastatic CRPC Patients in Japan
7. Appendix
7.1. Bibliography
7.2. Report Methodology
8. DelveInsight Capabilities
9. Disclaimer
10. About DelveInsight
Figure 1 CRPC SWOT Analysis
Figure 2 Prostate Cancer
Figure 3 Sign and Symptoms of Prostate Cancer
Figure 4 Risks Factors of Prostate Cancer
Figure 5 Pathophysiology of Prostate Cancer
Figure 6 Progression of Prostate Cancer and the Development of mCRPC
Figure 7 Diagnosis of Prostate Cancer
Figure 8 Gleason Score of Prostate Cancer
Figure 9 Global Heat Map of Prostate Cancer
Figure 10 Total Prevalent Cases of Prostate Cancer in the 7MM (2017–2030)
Figure 11 Total Diagnosed Cases of Prostate Cancer by Clinical Stages in the 7MM (2017–2030)
Figure 12 Total Non-metastatic Cases of CRPC in the 7MM (2017–2030)
Figure 13 Total Metastatic Cases of CRPC in the 7MM (2017–2030)
Figure 14 Total Treated Cases of nmCRPC by Line of Therapies in the 7MM (2017–2030)
Figure 15 Total Treated Cases of mCRPC by Line of Therapies in the 7MM (2017–2030)
Figure 16 Total Diagnosed Cases of Prostate Cancer in the United States (2017–2030)
Figure 17 Age-specific Cases of Prostate Cancer in the United States (2017–2030)
Figure 18 Total Diagnosed Cases of Prostate Cancer by Clinical Stages in the United States (2017–2030)
Figure 19 Total Non-metastatic Cases of CRPC in the United States (2017–2030)
Figure 20 Total Metastatic Cases of CRPC in the United States (2017–2030)
Figure 21 Total Treated Cases of nmCRPC by Line of Therapies in the United States (2017–2030)
Figure 22 Total Treated Cases of mCRPC by Line of Therapies in the United States (2017–2030)
Figure 23 Total Diagnosed Prevalent cases of Prostate Cancer in Germany (2017–2030)
Figure 24 Age-specific Diagnosed Prevalent cases of Prostate Cancer in Germany (2017–2030)
Figure 25 Total Diagnosed Prevalent cases of Prostate Cancer by Clinical Stages in Germany (2017–2030)
Figure 26 Total Non-metastatic Cases of CRPC in Germany (2017–2030)
Figure 27 Total Metastatic Cases of CRPC in Germany 2017–2030)
Figure 28 Total Treated Cases of nmCRPC by Line of Therapies in Germany (2017–2030)
Figure 29 Total Treated Cases of mCRPC by Line of Therapies in Germany (2017–2030)
Figure 30 Total Diagnosed Prevalent cases of Prostate Cancer in France (2017–2030)
Figure 31 Age-specific Diagnosed Prevalent cases of Prostate Cancer in France (2017–2030)
Figure 32 Total Diagnosed Prevalent cases of Prostate Cancer by Clinical Stages in France (2017–2030)
Figure 33 Total Non-metastatic Cases of CRPC in France (2017–2030)
Figure 34 Total Metastatic Cases of CRPC in France2017–2030)
Figure 35 Total Treated Cases of nmCRPC by Line of Therapies in France (2017–2030)
Figure 36 Total Treated Cases of mCRPC by Line of Therapies in France (2017–2030)
Figure 37 Total Diagnosed Prevalent cases of Prostate Cancer in Italy (2017–2030)
Figure 38 Age-specific Diagnosed Prevalent cases of Prostate Cancer in Italy (2017–2030)
Figure 39 Total Diagnosed Prevalent cases of Prostate Cancer by Clinical Stages in Italy (2017–2030)
Figure 40 Total Non-metastatic Cases of CRPC in Italy (2017–2030)
Figure 41 Total Metastatic Cases of CRPC in Italy 2017–2030)
Figure 42 Total Treated Cases of nmCRPC by Line of Therapies in Italy (2017–2030)
Figure 43 Total Treated Cases of mCRPC by Line of Therapies in Italy (2017–2030)
Figure 44 Total Diagnosed Prevalent cases of Prostate Cancer in Spain (2017–2030)
Figure 45 Age-specific Diagnosed Prevalent cases of Prostate Cancer in Spain (2017–2030)
Figure 46 Total Diagnosed Prevalent cases of Prostate Cancer by Clinical Stages in Spain (2017–2030)
Figure 47 Total Non-metastatic Cases of CRPC in Spain (2017–2030)
Figure 48 Total Metastatic Cases of CRPC in Spain (2017–2030)
Figure 49 Total Treated Cases of nmCRPC by Line of Therapies in Spain (2017–2030)
Figure 50 Total Treated Cases of mCRPC by Line of Therapies in Spain (2017–2030)
Figure 51 Total Diagnosed Prevalent cases of Prostate Cancer in the United Kingdom (2017–2030)
Figure 52 Age-specific Diagnosed Prevalent cases of Prostate Cancer in the United Kingdom (2017–2030)
Figure 53 Total Diagnosed Prevalent cases of Prostate Cancer by Clinical Stages in the United Kingdom (2017–2030)
Figure 54 Total Non-metastatic Cases of CRPC in the United Kingdom (2017–2030)
Figure 55 Total Metastatic Cases of CRPC in the United Kingdom (2017–2030)
Figure 56 Total Treated Cases of nmCRPC by Line of Therapies in the United Kingdom (2017–2030)
Figure 57 Total Treated Cases of mCRPC by Line of Therapies in the United Kingdom (2017–2030)
Figure 58 Total Diagnosed Prevalent cases of Prostate Cancer in Japan (2017–2030)
Figure 59 Age-specific Diagnosed Prevalent cases of Prostate Cancer in Japan (2017–2030)
Figure 60 Total Diagnosed Prevalent cases of Prostate Cancer by Clinical Stages in Japan (2017–2030)
Figure 61 Total Non-metastatic Cases of CRPC in Japan (2017–2030)
Figure 62 Total Metastatic Cases of CRPC in Japan (2017–2030)
Figure 63 Total Treated Cases of nmCRPC by Line of Therapies in Japan (2017–2030)
Figure 64 Total Treated Cases of mCRPC by Line of Therapies in Japan (2017–2030)
【免責事項】
https://www.marketreport.jp/reports-disclaimer